CHOLESTEROL TEST KIT SALES BUSINESS PLAN

I. Executive Summary

Company Description

Founded for a 2026 launch, the company name—PulseHome—reflects our focus on everyday cardiovascular vigilance. We operate in the preventative healthcare sector as a direct-to-consumer e-commerce platform based in Austin, Texas, selling FDA-approved at-home cholesterol testing kits and curated health bundles nationwide. Our primary offerings combine single-purchase, high-margin testing kits with a recurring subscription service that includes repeat testing, results tracking, and optional clinician referrals. PulseHome packages clinical-grade accuracy with a consumer-first experience. One clear line: we put private, clinical cholesterol data in users’ hands.

We deliver via a robust technology stack and a specialized 3PL that manages inventory, fulfillment, and returns; our platform handles ordering, reminders, and data visualization to drive ongoing engagement. Target customers are digitally engaged adults focused on preventative cardiovascular care and long-term monitoring. Short-term goals are to launch operations in 2026 and establish customer acquisition channels; long-term goals are to scale nationwide subscription penetration and become a leader in home cardiovascular monitoring. Our advantage is clinical validity plus seamless recurring care. One clear line: we turn one-time tests into continuous prevention.

Problem

Millions of Americans have high cholesterol, a leading risk factor for heart disease, yet routine lab testing remains inconvenient and time-consuming; lack of convenient testing prevents timely action. Current care depends on infrequent clinic visits and lab trips, so many people go long periods without data to guide medication adjustments or lifestyle changes.

Existing options underserve people with busy schedules, limited mobility, or privacy concerns and do not provide a private, accessible at‑home tracking path. This gap creates monitoring gaps, delayed care, and missed prevention opportunities—calling for a direct-to-consumer, at-home solution that delivers FDA-approved testing and ongoing engagement.

Solution

Millions of Americans face elevated heart-disease risk because routine lipid monitoring is infrequent and burdensome; we offer FDA-approved, user-friendly at-home cholesterol test kits sold through a medical-grade e-commerce platform, with basic single-test kits and premium repeat-testing bundles that enable private, on-schedule lipid checks and reduce routine lab visits.

One line: at-home testing that replaces lab visits for routine lipid monitoring.

Mission Statement

We empower individuals to control their cardiovascular wellness by providing accessible, private, and reliable FDA-approved at-home diagnostic solutions. We make heart health monitoring a seamless part of daily life through trustworthy products, e-commerce convenience, and clear data that enable proactive care. Our goal is to reduce the impact of heart disease across the United States by putting accurate, private health information directly into people’s hands.

Key Success Factors

Success depends on cost-efficient acquisition, repeat buyers, a high-margin product mix, scalable operations, and trusted, compliant products.

• Low CAC: Customer Acquisition Cost declining to $18 by 2029.
• High retention: Repeat customer rate reaching 45% by Year 5.
• Premium mix: Premium Heart Health Bundle growing to 40% of sales.
• Scalable ops: 3PL partnership plus packaging automation to control overhead.
• Regulatory trust: FDA-approved products and excellent customer service.

Financial Summary

Concise financial snapshot showing revenue scale-up, path to EBITDA profitability, and investor returns.

Financial requirements: $220,000 total launch capex, minimum cash $524,000 (Jan-27), payback 26 months; breakeven Feb-27. Anticipated return: IRR 10.67% and 35.72% ROE over the initial five-year period.

Outlook: profitable growth to $27.35M revenue and $21.48M EBITDA by 2030 on conservative cost and inventory assumptions.

Funding Requirements

We require $744,000 to launch the cholesterol test kit business and reach breakeven by Feb-2027 under the current plan.